Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
14 Août 2017 - 10:53PM
Edgar (US Regulatory)
|
|
OMB APPROVAL
|
UNITED STATES
|
|
SECURITIES AND EXCHANGE
|
OMB Number: 3235-0058
|
COMMISSION
|
Expires: October 31, 2018
|
Washington, D.C. 20549
|
Estimated average burden hours per
|
|
response: 2.50
|
FORM 12b-25
|
|
|
SEC FILE NUMBER
|
NOTIFICATION OF LATE FILING
|
001-36602
|
|
|
|
CUSIP NUMBER
|
|
45254C101
|
(Check one):
|
¨
Form 10-K
¨
Form 20-F
¨
Form 11-K
x
Form 10-Q
¨
Form 10-D
¨
Form N-SAR
¨
Form N-CSR
|
|
|
|
For Period Ended:
|
June 30, 2017
|
|
¨
Transition Report on Form 10-K
|
|
¨
Transition Report on Form 20-F
|
|
¨
Transition Report on Form 11-K
|
|
¨
Transition Report on Form 10-Q
|
|
¨
Transition Report on Form N-SAR
|
|
|
|
For the Transition Period Ended:
|
Read Instruction (on back page) Before
Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has verified any information
contained herein.
If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
IMMUNE PHARMACEUTICALS INC.
Full Name of Registrant
N/A
Former Name if Applicable
550 Sylvan Avenue
Address of Principal Executive Office (Street and Number)
Englewood
Cliffs, NJ 07632
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable
effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if
appropriate)
|
(a)
|
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
¨
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR, or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail the reasons why Forms 10-K,
20-F, 11-K, 10-Q, N-SAR, or the transition report portion thereof, could not be filed within the prescribed time period.
The compilation, dissemination and review of the
information required to be presented in the Immune Pharmaceuticals Inc. (the “Company”) Form 10-Q for the period ending
June 30, 2017 (“Form 10-Q”) could not be completed within the prescribed time period without undue hardship and expense
for the registrant. The Company will file the Form 10-Q within the 5-day extension period.
SEC 1344 (03-05)
|
Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
(Attach extra Sheets if Needed)
PART IV — OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
|
|
|
|
John C. Militello
|
|
(201)
|
|
464-2677
|
|
|
(Area Code)
|
(Telephone Number)
|
|
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).
|
|
Yes
x
No
¨
|
|
(3)
|
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
Yes
¨
No
x
|
|
If so, attach an explanation of the anticipated change,
both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.
|
Immune
Pharmaceuticals Inc.
(Name of Registrant as Specified
in Charter)
has caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 14, 2017
|
By:
|
/s/ John C. Militello
|
|
|
|
John C. Militello
|
|
|
|
VP of Finance, Controller
|
|
|
|
and Chief Accounting Officer
|
|
INSTRUCTION: The form may be signed by an executive officer
of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed
or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other
than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed
with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)
(USOTC:IMNPQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(USOTC:IMNPQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024